179 related articles for article (PubMed ID: 20431575)
1. Ironing out the phosphorus problem.
Zaritsky JJ; Salusky IB
Kidney Int; 2010 May; 77(10):845-7. PubMed ID: 20431575
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of SBR759, a new iron-based phosphate binder.
Block GA; Brillhart SL; Persky MS; Amer A; Slade AJ
Kidney Int; 2010 May; 77(10):897-903. PubMed ID: 20375984
[TBL] [Abstract][Full Text] [Related]
3. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
Slatopolsky EA; Burke SK; Dillon MA
Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
[TBL] [Abstract][Full Text] [Related]
4. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease.
Navaneethan SD; Sakhuja A; Arrigain S; Sharp J; Schold JD; Nally JV
Clin Nephrol; 2014 Jul; 82(1):16-25. PubMed ID: 24887302
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
6. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
7. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
[TBL] [Abstract][Full Text] [Related]
8. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Calcium carbonate as a phosphate binder in hemodialysis patients.
Taber TE; Hegemen TF; York S
ASAIO Trans; 1986; 32(1):127-9. PubMed ID: 3778697
[TBL] [Abstract][Full Text] [Related]
11. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
12. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
13. Novel iron-based phosphate binders in patients with chronic kidney disease.
Shah HH; Hazzan AD; Fishbane S
Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
15. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
[TBL] [Abstract][Full Text] [Related]
16. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
[TBL] [Abstract][Full Text] [Related]
18. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
[TBL] [Abstract][Full Text] [Related]
19. Novel dosage forms and regimens for sevelamer-based phosphate binders.
Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
